ASCO: Nexavar thyroid cancer data add to Onyx, Bayer oncology growth
This article was originally published in Scrip
Executive Summary
Positive Phase III data for Nexavar (sorafenib) in the treatment of thyroid cancer patients who've run out of approved therapeutic options will support regulatory submissions for the Onyx Pharmaceuticals and Bayer HealthCare kinase inhibitor – and provide incremental growth for the companies' growing oncology portfolios.